ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Integrative omics profiling of CRELD2 in ccRCC: a nexus of genetics, prognosis, and tumor microenvironment.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most common and aggressive form of renal malignancy. Although therapeutic strategies such as targeted agents and immune checkpoint inhibitors have progressed, the prognosis for patients with advanced ccRCC remains unsatisfactory. Cysteine-rich epidermal growth factor-like domain 2 (CRELD2), a protein localized to the endoplasmic reticulum, is involved in several biological processes, yet its function in ccRCC has not been clearly characterized.
methodsWe conducted an integrative multi-omics study to investigate the role of CRELD2 in ccRCC. The study incorporated mendelian randomization (MR), bulk and single-cell RNA sequencing, immunohistochemistry, immune infiltration analysis, and spatial transcriptomics to explore expression patterns, prognostic value, cellular distribution, and potential biological implications of CRELD2.
resultsMR and summary-data-based MR analyses identified CRELD2 as a genetically supported candidate associated with RCC susceptibility. Elevated CRELD2 expression was confirmed at both mRNA and protein levels in ccRCC and correlated with worse overall survival independently. Single-cell analysis revealed preferential CRELD2 enrichment in endothelial and B-cell compartments, with CRELD2-high subsets showing shared enrichment of TNFA/NFκB, MTORC1, ROS, and oxidative phosphorylation pathways. Immune infiltration analysis linked CRELD2 expression to a B-cell-related immune infiltration profile, while spatial transcriptomics showed CRELD2 enrichment in tertiary lymphoid structure (TLS)-associated regions. Across single-cell and spatial analyses, TNFA/NFκB-related immune-inflammatory signaling represented a recurrent CRELD2-associated pathway feature.
conclusionThis study pointed out the CRELD2-centered TLS-associated immune-inflammatory conceptual axis, linking CRELD2 expression, endothelial/B-cell cellular contexts, B-cell-related immune infiltration, TLS-associated spatial localization, and recurrent TNFA/NFκB pathway enrichment via multi-omics and supporting it as a candidate therapeutic biomarker in ccRCC for further functional investigations.
Indexed as
Identifiers
42700259What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.